Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Shutdown leaves 1.4M workers unpaid, costs billions as vital services are disrupted and small businesses denied capital.
ECB maintains steady rates amid Eurozone resilience, contrasting with Fed's rate cuts opposed by some officials
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Shutdown leaves 1.4M workers unpaid, costs billions as vital services are disrupted and small businesses denied capital.
ECB maintains steady rates amid Eurozone resilience, contrasting with Fed's rate cuts opposed by some officials